Valuation: Kalaris Therapeutics, Inc.

Market Cap 59.51M 53.08M 49.48M 44.98M 84.65M 5.76B 85.51M 594M 232M 2.94B 223M 219M 9.4B P/E 2026 *
-1.25x
P/E 2027 * -1.59x
Enterprise Value 4.17M 3.72M 3.47M 3.15M 5.93M 404M 5.99M 41.6M 16.28M 206M 15.65M 15.32M 659M EV / Sales 2026 *
-
EV / Sales 2027 * -5.91x
Free-Float
91.19%
Yield 2026 *
-
Yield 2027 * -
1 day-3.76%
1 week-11.42%
Current month-11.42%
1 month-34.36%
3 months-47.00%
6 months-60.37%
Current year-69.67%
1 week 2.35
Extreme 2.35
2.93
1 month 2.35
Extreme 2.35
3.68
Current year 2.35
Extreme 2.35
11.22
1 year 2.35
Extreme 2.35
11.88
3 years 2.14
Extreme 2.14
12.9
5 years 2.14
Extreme 2.14
12.9
10 years 2.14
Extreme 2.14
12.9
Date Insider Type Main position Quantity % Market Cap. Importance
8/27/26 Free

Controller/Auditor

10,000 0.0420%
8/1/26 Free

Director

18,000 0.0757%
7/27/26 Other

Controller/Auditor

48,363 0.2033%
Change 5-day change 1-year change 3-year change Capi.($)
-3.76%-11.42%-66.84% - 60.94M
-3.19%-3.19%+44.60%+87.98% 74.68B
-15.86%-16.67%+3.92%+50.90% 58.7B
-2.39%-2.05%+4.29%+31.33% 48.36B
-6.35%-8.35%+303.95%+651.28% 43.05B
+0.30%-3.71%+28.89%+30.33% 42.48B
-3.82%-4.32%+2.49%+101.36% 41.39B
-2.13%+1.07%+7.51%+50.31% 31.29B
-3.35%-6.35%-13.20%-17.22% 23.93B
-1.24%-11.97%-38.10%+311.13% 22.22B
Average -3.86%-3.38%+27.75%+144.16% 38.62B
Weighted average by Cap. -4.67%-1.88%+44.68%+136.42%

Financials

2026 *2027 *
Net sales - 11.43M 10.19M 9.5M 8.64M 16.26M 1.11B 16.42M 114M 44.6M 564M 42.89M 41.97M 1.81B
Net income -48.31M -43.09M -40.17M -36.52M -68.72M -4.68B -69.42M -482M -189M -2.38B -181M -177M -7.63B -47.76M -42.6M -39.71M -36.1M -67.94M -4.62B -68.63M -476M -186M -2.36B -179M -175M -7.54B
Net Debt -55.34M -49.36M -46.01M -41.83M -78.72M -5.36B -79.52M -552M -216M -2.73B -208M -203M -8.74B -127M -113M -106M -96.02M -181M -12.29B -183M -1.27B -496M -6.27B -477M -467M -20.06B
Projected Income Statement - Annual - Kalaris Therapeutics, Inc.
Logo Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Employees
20
Date Price Change Volume
26-10-08 US$2.500 -2.34% 109,961
26-10-07 US$2.560 -3.76% 74,117
26-10-06 US$2.660 -6.01% 103,434
26-10-05 US$2.830 +4.81% 27,389
26-10-02 US$2.700 -5.26% 235,897
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Ratings Surperformance© - Kalaris Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.500USD
Average target price
18.71USD
Spread / Average Target
+648.57%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Kalaris Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. KLRS Stock